Mechanisms of checkpoint inhibition-induced adverse events. (2020)
Attributed to:
Preclinical efficacy of an antibody of the IgE class against a melanoma-associated antigen
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1111/cei.13421
PubMed Identifier: 31989585
Publication URI: http://europepmc.org/abstract/MED/31989585
Type: Journal Article/Review
Volume: 200
Parent Publication: Clinical and experimental immunology
Issue: 2
ISSN: 0009-9104